Alvotech

Annually, Alvotech releases an Equality Report. Recently we released our report for 2023. Alvotech’s Equality Policy is based on Icelandic law but has been implemented globally for all our employees. Our Equal Pay Management System certification is issued by the Icelandic Directorate of Equality and we were recently recertified by the British Standards Institute. In 2023 the unexplained gender pay gap had fallen to 0.6% for employees globally from 5.2% in December 2020, and to 0.7% for employees in Iceland. In 2023, 51% of new hires were women and 55% of job progressions or promotions were women. Alvotech’s equality policy and related disclosure is part of a broader corporate sustainability initiative. The report can be viewed on Alvotech’s Corporate Sustainability portal: https://ow.ly/2sst50Sy5MC. #ESG #equalpay #biosimilars #HealthcareAccess

To improve #HealthcareAccess for all - Alvotech makes both #biosimilars and future leaders. We were of course extremely proud to see the names of Hörður Kári Harðarson, Head of Process and Product Development, and Snorri Páll Sigurðsson, Head of Logistics, on the list of rising stars in Icelandic business this week. 👏 Hörður was named on the '40 under 40' list and Snorri on the 'Rising Stars' list, both published biannually by local PR and HR consultancy Góð samskipti. Congratulations on an honor well-deserved! 🥳 #Leadership #RisingStars

Harshika Sarbajna, Alvotech's VP Commercial & Head Global is a co-chair of the 15th Summit on Biosimilars & Innovator Biologics in NYC, June 20-21. This year could be transformative for the biosimilars and biologics market in the U.S., so there is certainly much to talk about. We look forward to an interesting event. #biosimilars #biologics #biosimilars24 American Conference Institute

We are pleased to grow our partnership with ADVANZ PHARMA, signing a new European commercialization agreement for a biosimilar candidate in eye disease. This demonstrates our common vision for the growth of #biosimilars and strong commitment to providing broader #healthcareaccess to high-quality and more affordable #biologics. Press release: https://ow.ly/Np9u50SkMIp

Thank's Dr. Reddy's Laboratories team. We at look forward to working together, providing better access to safe and effective biologics. Combining our resources will ensure that patients globally can be better served. #healthcareaccess #biosimilars

Thanks to all our guests at Alvotech's Iceland Innovation Week 2024 event. If you were not able to attend, here is a video of the presentations. "Alvotech: How was it made?“: 👉https://ow.ly/y64s50RJvOm

Register for our event during Iceland Innovation Week, May 15 at 5 pm in Sæmundargata 15-19, Reykjavik. Tanya Zharov, Sesselja Omarsdottir and Lilja Kjalarsdottir talk about Alvotech: How it was made - Pivotal stories from our journey. Skráning stendur yfir á atburð Alvotech í Iceland Innovation Week kl. 17 miðvikudaginn 15. maí nk., í Sæmundargötu 15-19. Þær Tanya Zharov, Sesselja Ómarsdóttir og Lilja Kjalarsdóttir fjalla um brot úr sögu Alvotech og næstu skref. https://lnkd.in/dx5tPy9u

Join us at Alvotech HQ in Reykjavik on Wednesday May 15, 2024, from 5-6 PM during Iceland Innovation Week 2024. We'll share stories about how we got here, and where we are headed. 👇 Please remember to register by using the link in the event below 👌

We‘re pleased to reveal our U.S. strategic partnership agreement with Quallent Pharmaceuticals, which will distribute under private label Alvotech‘s interchangeable biosimilar, recently approved by the FDA for various autoimmune conditions such as rheumatoid arthritis. Our aim is to provide cost savings for healthcare systems and more affordable high quality biologics for patients in need. Read all about it: https://ow.ly/5Zbq50RssOE

Exciting results out today as we become the first company announcing positive topline results from a confirmatory patient study for a biosimilar candidate referencing an important biologic treatment in chronic inflammatory disease. We expect to file marketing applications in major markets later this year. More on our website: https://ow.ly/w6Z750Rn01N #HealthcareAccess #biosimilars